In the latest podcast in the “Clinical Trials in Genitourinary Cancers” series, experts discuss 3 clinical trials testing potential new treatments for prostate, bladder, and kidney cancers.
Programa científico virtual de ASCO20: Inmunoterapia para el cáncer colorrectal metastásico, terapia de mantenimiento para el cáncer de vejiga, medicina de precisión para el cáncer infantil, inmunoterapia para la ETG y terapia dirigida para el NSCLC
Lea los puntos destacados de la investigación del programa científico virtual ASCO20 que se acaban de publicar. Incluyen estudios sobre inmunoterapia para el cáncer colorrectal metastásico y la enfermedad trofoblástica gestacional, terapia de mantenimiento para el cáncer de vejiga avanzado, el potencial de la medicina de precisión para el cáncer infantil y la terapia dirigida después de la cirugía por EGFR (receptor del factor de crecimiento epidérmico), positivo de cáncer de pulmón de células no pequeñas.
ASCO20 Virtual Scientific Program: Immunotherapy for Colorectal Cancer, Maintenance Therapy for Bladder Cancer, Precision Medicine in Childhood Cancers, Treatment for Gestational Trophoblastic Disease, and Targeted Therapy for Non-Small Cell Lung Cancer
Read research highlights just released from the ASCO20 Virtual Scientific Program. They include studies on immunotherapy for metastatic colorectal cancer and gestational trophoblastic disease, maintenance therapy for advanced bladder cancer, the potential of precision medicine for childhood cancers, and targeted therapy after surgery for EGFR-positive non-small cell lung cancer.
In this Clinical Trials in Genitourinary Cancers series podcast, experts discuss 3 clinical trials aiming to identify new treatments for prostate, bladder, and kidney cancers.
Clinical Trials in Genitourinary Cancers: Investigating New Treatments for Kidney, Bladder, and Prostate Cancers
In the first podcast of the Clinical Trials in Genitourinary Cancers series, experts discuss 3 clinical trials that are currently exploring new ways of treating kidney, bladder, and prostate cancers.
ASCO Annual Meeting 2019: Laparoscopic Surgery for Metastatic Colorectal Cancer, Expanding Eligibility Criteria for Advanced Non-Small Cell Lung Cancer, and a New Targeted Therapy for Advanced Bladder Cancer
The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include minimally invasive surgery for liver metastases in colorectal cancer, expanding clinical trial eligibility criteria for non-small cell lung cancer, and a new targeted therapy for advanced bladder cancer.
The 2018 Genitourinary Cancers Symposium includes exciting research that focuses on effective treatment options for kidney cancer, prostate cancer, and bladder cancer.
The 2017 Clinical Cancer Advances report of the American Society of Clinical Oncology has announced that the Advance of the Year is Immunotherapy 2.0. Why 2.0? Because the role of immunotherapy in cancer care is expanding, and oncologists are learning how to use it more effectively.
Experts discuss new research advances in bladder, kidney, colorectal, pancreatic, and stomach cancers in these two Research Round Up podcasts.
These studies from the ASCO Annual Meeting show some of the newest thoughts and latest advances in using immunotherapy and targeted therapy to treat bladder, stomach, and lung cancers.